ARENTFOX SCHIFF LLP for ORGANOGENESIS INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System regulations regarding reimbursement for chronic wound healing product Physician Fee Schedule regulations regarding reimbursement for chronic wound healing product
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICE HOWARD New | — |
| DAN RENBERG | — |
| OLIVER SPURGEON III | — |
Health Issues HCR
Food and Drug Administration policy on chronic wound healing products H.R. 6000 (Cures 2.0 Act), Title III, regarding Food and Drug Administration policy on chronic wound healing products S. 4348 (FDASLA Act of 2022), regarding Food and Drug Administration policy on chronic wound healing products H.R. 7667 (Food and Drug Amendments of 2022), regarding Food and Drug Administration policy on chronic wound healing products
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAN RENBERG | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.